BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 10738999)

  • 1. A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia.
    Rosen PJ; Rankin C; Head DR; Boldt DH; Luthardt FW; Norwood T; Pugh RP; Karanes C; Appelbaum FR
    Leuk Res; 2000 Mar; 24(3):183-7. PubMed ID: 10738999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitoxantrone and continuous infusion of cytosine arabinoside in refractory and relapsed acute lymphoblastic leukemia.
    Liso V; Specchia G; Capalbo S; Pavone V; Iacobazzi A; Iaculli ML; Dione R; Pansini N
    Acta Haematol; 1992; 87(1-2):54-7. PubMed ID: 1585771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitoxantrone and standard dose cytosine arabinoside therapy in refractory or relapsed acute leukemia.
    Keskin A; Tombuloğlu M; Atamer MA; Büyükkeçeci F
    Acta Haematol; 1994; 92(1):14-7. PubMed ID: 7985476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study.
    Karanes C; Kopecky KJ; Head DR; Grever MR; Hynes HE; Kraut EH; Vial RH; Lichtin A; Nand S; Samlowski WE; Appelbaum FR
    Leuk Res; 1999 Sep; 23(9):787-94. PubMed ID: 10475617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine.
    Raanani P; Shpilberg O; Gillis S; Avigdor A; Hardan I; Berkowicz M; Sofer O; Lossos I; Chetrit A; Ben-Yehuda D; Ben-Bassat I
    Leuk Res; 1999 Aug; 23(8):695-700. PubMed ID: 10456666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone.
    Weiss M; Maslak P; Feldman E; Berman E; Bertino J; Gee T; Megherian L; Seiter K; Scheinberg D; Golde D
    J Clin Oncol; 1996 Sep; 14(9):2480-5. PubMed ID: 8823326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
    Karp JE; Passaniti A; Gojo I; Kaufmann S; Bible K; Garimella TS; Greer J; Briel J; Smith BD; Gore SD; Tidwell ML; Ross DD; Wright JJ; Colevas AD; Bauer KS
    Clin Cancer Res; 2005 Dec; 11(23):8403-12. PubMed ID: 16322302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy.
    Milpied N; Gisselbrecht C; Harousseau JL; Sebban C; Witz F; Troussard X; Gratecos N; Michallet M; LeBlond V; Auzanneau G
    Cancer; 1990 Aug; 66(4):627-31. PubMed ID: 2386891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM).
    Hiddemann W; Büchner T; Heil G; Schumacher K; Diedrich H; Maschmeyer G; Ho AD; Planker M; Gerith-Stolzenburg S; Donhuijsen-Ant R
    Leukemia; 1990 Sep; 4(9):637-40. PubMed ID: 2395383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.
    Ozkaynak MF; Avramis VI; Carcich S; Ortega JA
    Med Pediatr Oncol; 1998 Dec; 31(6):475-82. PubMed ID: 9835899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia.
    Paciucci PA; Cuttner J; Holland JF
    Am J Hematol; 1990 Sep; 35(1):22-5. PubMed ID: 2202204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
    Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Planker M; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):73-7. PubMed ID: 3473685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen.
    Sternberg DW; Aird W; Neuberg D; Thompson L; MacNeill K; Amrein P; Shulman LN
    Cancer; 2000 May; 88(9):2037-41. PubMed ID: 10813714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of mitoxantrone and Ara-C with or without etoposide salvage chemotherapy in adult patients with relapsed or refractory acute lymphoblastic leukemia: retrospective multicenter study of the Korean Adult ALL Working Party.
    Ahn JS; Yang DH; Jung SH; Lee JJ; Kim I; Park S; Chung JS; Shin HJ; Kim DY; Lee KH; Moon JH; Sohn SK; Song IC; Jo DY; Joo YD;
    Acta Haematol; 2015; 133(1):91-7. PubMed ID: 25171064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD7 positive acute lymphoblastic leukemia successfully treated with high dose cytosine arabinoside and mitoxantrone: a case report.
    Nakajima H; Kizaki M; Kawai Y; Ishida A; Tokuhira M; Watanabe K; Ikeda Y
    Keio J Med; 1996 Jun; 45(2):114-7. PubMed ID: 8683901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients.
    Lejeune C; Tubiana N; Gastaut JA; Maraninchi D; Richard B; Launay MC; Sainty D; Sebahoun G; Carcassonne Y
    Eur J Haematol; 1990 Apr; 44(4):240-3. PubMed ID: 2344886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
    Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia.
    Arlin ZA; Feldman EJ; Finger LR; Ahmed T; Mittelman A; Cook P; Puccio C; Baskind P; Arnold P; Razis ED
    Leukemia; 1991 Aug; 5(8):712-4. PubMed ID: 1886423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
    Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.